济元基因 iPSC 来源通用现货细胞治疗产品获美国 FDA IND 许可

Phase 1approvedCG101 注射液 (CG101 Injection)Positive

AI Analysis

Summary

Jiyuan Gene announced FDA IND approval for CG101, a gene-edited iPSC-derived universal off-the-shelf immune cell therapy for acute myeloid leukemia, marking China's first FDA IND approval for such a product and the company's entry into global clinical development.

Clinical Trial Data

Phase

Phase 1

Outcome Details

FDA IND application approved for CG101, a gene-edited iPSC-derived universal off-the-shelf immune cell therapy for AML

Importance:7/10

Sentiment:

0.85

IND ApprovaliPSC TechnologyGene-Edited Cell TherapyOff-the-Shelf CellsAcute Myeloid LeukemiaChinaFirst FDA IND for gene-edited iPSC immunotherapy from China

Read the original article

Published by PR Newswire Clinical Trials on August 14, 2026 12:00 AM

Read Original